Research programme: cannabidiol-combination therapies - Enveric Biosciences
Latest Information Update: 27 Feb 2024
Price :
$50 *
At a glance
- Originator Tikun Olam
- Developer Enveric Biosciences
- Class Analgesics; Anti-inflammatories; Antibacterials; Antineoplastics; Cannabinoids; Immunotherapies; Neuroprotectants; Skin disorder therapies
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioblastoma; Radiodermatitis
- Research Peripheral nervous system diseases
Most Recent Events
- 23 Feb 2024 Unknown company acquires patent portfolio related to combination of cannabidiol and second therapeutic agents from Enveric Biosciences
- 18 Aug 2021 Enveric Biosciences has patent protection for Cannabinoids for the treatment of Cancer in USA
- 19 Jan 2021 Enveric Biosciences plans a phase I/II trial for Radiodermatitis in the US in 2021